Centessa Pharmaceuticals plc (NASDAQ:CNTA) Given Average Rating of "Buy" by Brokerages

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) have been assigned a consensus recommendation of "Buy" from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average 12 month price target among analysts that have covered the stock in the last year is $26.00.

CNTA has been the topic of a number of analyst reports. Guggenheim reaffirmed a "buy" rating on shares of Centessa Pharmaceuticals in a research note on Monday, February 10th. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a "buy" rating on the stock. Finally, Morgan Stanley reaffirmed an "overweight" rating and issued a $27.00 price target on shares of Centessa Pharmaceuticals in a report on Friday, March 7th.

Centessa Pharmaceuticals Stock Performance

Centessa Pharmaceuticals stock traded down $0.19 during trading on Thursday, reaching $16.87. The company had a trading volume of 1,245,330 shares, compared to its average volume of 861,713. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals has a 52 week low of $7.75 and a 52 week high of $19.09. The firm has a market capitalization of $2.22 billion, a price-to-earnings ratio of -11.03 and a beta of 1.54. The firm's 50-day simple moving average is $16.45 and its 200 day simple moving average is $16.25.

Remove Ads

Insiders Place Their Bets

In other news, insider Gregory M. Weinhoff sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $17.04, for a total transaction of $170,400.00. Following the transaction, the insider now owns 183,266 shares in the company, valued at $3,122,852.64. The trade was a 5.17 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Karen M. Anderson sold 30,526 shares of the business's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $19.03, for a total transaction of $580,909.78. Following the transaction, the insider now directly owns 54,322 shares in the company, valued at approximately $1,033,747.66. The trade was a 35.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 359,186 shares of company stock valued at $6,017,106 in the last ninety days. 11.59% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD raised its position in shares of Centessa Pharmaceuticals by 14.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company's stock valued at $89,854,000 after buying an additional 685,371 shares during the period. Adage Capital Partners GP L.L.C. increased its stake in Centessa Pharmaceuticals by 22.0% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company's stock worth $85,744,000 after acquiring an additional 924,027 shares during the last quarter. Janus Henderson Group PLC increased its stake in Centessa Pharmaceuticals by 279.2% during the fourth quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company's stock worth $82,218,000 after acquiring an additional 3,614,623 shares during the last quarter. Farallon Capital Management LLC lifted its stake in shares of Centessa Pharmaceuticals by 24.3% in the 4th quarter. Farallon Capital Management LLC now owns 3,498,709 shares of the company's stock valued at $58,603,000 after purchasing an additional 684,391 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its stake in shares of Centessa Pharmaceuticals by 26.2% in the 4th quarter. Point72 Asset Management L.P. now owns 3,426,599 shares of the company's stock valued at $57,396,000 after purchasing an additional 710,936 shares during the last quarter. 82.01% of the stock is owned by hedge funds and other institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.